mardi 28 avril 2020

Onco Actu du 28 avril 2020


2.5 ETIOLOGIE - GÉNOME



Scientists double understanding of genetic risk of melanoma [University of Leeds]











3.1.1 PRÉVENTION - TABAC - E-CIGS



FDA Warns Manufacturers and Retailers to Remove Certain E-cigarette Products Targeted to Youth from the Market [FDA]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



New clues about why some metastatic prostate cancers don't respond to enzalutamide [EurekAlert!]











5.12 IMMUNOTHÉRAPIES



Immunotherapy Before Surgery Could Advance Care of an Aggressive Form of Skin Cancer [Johns Hopkins]











5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE



Immune system changes occur early in development of multiple myeloma, study finds [Dana-Farber Cancer Institute]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



Promising new treatment for recurrent pediatric brain cancer [Baylor]










5.12.5 IMMUNOTHÉRAPIES - PHARMA



Boehringer Ingelheim VC backs plan to send GMO bacteria after tumors [EndPoints]











Phase 3 Trial of Libtayo® (cemiplimab) as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival [Regeneron]











Regeneron, Sanofi immunotherapy extends survival in previously untreated lung cancer [Biopharma Dive]











Sanofi, Regeneron take aim at Keytruda with Libtayo's first lung cancer win [Fierce Pharma]










5.2 PHARMA



Takeda Announces U.S. FDA Breakthrough Therapy Designation for Mobocertinib (TAK-788) for the Treatment of NSCLC Patients with EGFR Exon 20 Insertion Mutations [Takeda]











5.2.6 PHARMA - BIOTECH



An oncology upstart with some deep-pocket VC connections has a unicorn-sized venture round to back the pipeline [EndPoints]











5.9 AACR



#AACR20 roundup: Tecentriq/Xtandi combo fails to show OS benefit, halting Roche's PD-L1 push into prostate cancer [EndPoints]











AACR Virtual Annual Meeting I: The Opening Session [Cancer Research Catalyst]











American Association for Cancer Research (AACR) 2020 Virtual Meeting Preview [OBR]










5.9.1 AACR - SEIN



Patients with advanced BRCA-mutated breast cancer found no overall survival benefit with talazoparib [MD Anderson Cancer Center]











Yale Cancer Center Study Shows Immunotherapy Prior to Surgery May Help Destroy High-Risk Breast Cancer [Yale]











5.9.10 AACR - COLORECTAL



AACR: Early Trovagene data offer hope for KRAS-mutant colon cancer [Fierce Biotech]











5.9.12 AACR - BIOPSIES LIQUIDES



GRAIL to Present New Data at the American Association for Cancer Research (AACR) Annual Meeting [Grail]











5.9.2 AACR - HÉMATO



AACR: Roche's Tecentriq doesn't amp up Gilead's Yescarta in lymphoma, early study says [Fierce Pharma]











5.9.3 AACR - MÉLANOME



Continuous dosing improves progression-free survival for melanoma patients with common mutations [EurekAlert!]











First Clinical Outcomes Evaluating Six-Week Dosing Schedule for Merck’s KEYTRUDA® (pembrolizumab) Presented at AACR Virtual Annual Meeting I [Merck]











5.9.4 AACR - POUMON



#AACR20: Early data suggest Novartis' Incyte-discovered MET inhibitor helps lung cancer patients with brain lesions [EndPoints]











5.9.5 AACR - CAR-T, THÉRAPIES CELLULAIRES



#AACR20: Iovance revels in promising lung cancer data out of Moffitt as TIL therapy triggers 2 complete responses [EndPoints]











AACR: Iovance details early responses to TIL cell therapy in lung cancer [Fierce Biotech]











AACR: A look at next-gen CAR-T therapies for blood cancers [Fierce Biotech]










5.9.7 AACR - DIVERS



MD Anderson, Ipsen advance new therapy with potential benefit for underserved lung and ovarian cancer patients [MD Anderson Cancer Center]











5.9.9 AACR - IMMUNOTHÉRAPIES



AACR: Compugen's checkpoint inhibitor keeps cancer in check [Fierce Biotech]











6.15 LUTTE CONTRE LES CANCERS - COVID-19



Exclusive: U.S. medical testing, cancer screenings plunge during coronavirus outbreak - data firm analysis [Reuters]